Hospital General de Tijuana, Secretaría de Salud de Baja California, Avenida Centenario 10851, Zona Río, CP 22680, Tijuana, Baja California, Mexico.
Hospital General Regional 20, Instituto Mexicano del Seguro Social, Boulevard Díaz Ordaz y Lázaro Cárdenas, La Meza, CP 22450, Tijuana, Baja California, Mexico.
Int J Hematol. 2020 Sep;112(3):418-421. doi: 10.1007/s12185-020-02882-1. Epub 2020 Apr 13.
Secondary lymphohistiocytosis is a severe inflammatory condition characterized by uncontrolled inflammatory response hyperactivation of antigen-presenting cells, hemophagocytosis, cytopenias, and multiorgan failure, and is secondary to subjacent pathologies such as cancer, infection, or immune disease. Standard treatment includes chemotherapy; however, this is not always possible or safe. Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor can reduce inflammation and cytokine activity and has been used in refractory cases and first-line treatment. Here, we present a 35-year-old patient with HIV infection and secondary lymphohistiocytosis due to CMV/EBV infection who was successfully treated with ruxolitinib as first-line therapy. He rapidly showed clinical and biochemical improvement and transfusion independence without complications.
继发性组织细胞增生症是一种严重的炎症性疾病，其特征是抗原呈递细胞的炎症反应失控性激活、噬血细胞现象、细胞减少症和多器官衰竭，继发于癌症、感染或自身免疫性疾病等基础疾病。标准治疗包括化疗；然而，这并不总是可行或安全的。鲁索利替尼是一种 Janus 激酶 (JAK) 1/2 抑制剂，可减轻炎症和细胞因子活性，已用于难治性病例和一线治疗。在这里，我们介绍了一名 35 岁的 HIV 感染患者，由于 CMV/EBV 感染导致继发性组织细胞增生症，他成功地接受了鲁索利替尼作为一线治疗。他迅速表现出临床和生化改善以及输血独立性，没有并发症。
